Biotech Astex Pharmaceuticals (NASDAQ: ASTX) made a huge pop today, after RBC gave the stock an upgrade to "outperform," calling it an "undiscovered gem" and raising the price target a whopping 40%. In this video, Motley Fool health-care analyst David Williamson tells investors about some potentially very exciting phase 2 data soon to be released by the company and gives us a picture of what it could mean for Astex if its trial data is as good as RBC thinks.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.